Longevipedia
Cellular Reprogramming
Techniques to reverse cellular aging through epigenetic reprogramming
PAGE CONTENTS
Cellular Reprogramming for Longevity
Overview
Benefits (evidence-graded)
Types of Reprogramming
Mechanism of Action
Dosage / protocol (research context)
Clinical Evidence
Benefits & risks summary (safety)
Precautions (table)
Startups and industry activity
Future Directions
See also
References
Evidence Database (core)

Cellular Reprogramming for Longevity

Cellular reprogramming involves resetting the epigenetic state of cells to a more youthful condition, potentially reversing age-related changes. This revolutionary field represents one of the most promising approaches to addressing fundamental aging processes at the cellular level, with the potential to transform how we treat age-related diseases and extend healthy lifespan.

Laboratory microscope and cellular research

Overview

Cellular reprogramming uses transcription factors or other methods to reset cellular identity and function. The goal is to reverse age-related epigenetic changes and restore youthful cellular function. This approach is based on the groundbreaking discovery that mature, differentiated cells can be converted back to a pluripotent state through the introduction of specific transcription factors.[1]

The field of cellular reprogramming for longevity has evolved rapidly since the initial discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka in 2006.[2] While complete reprogramming to pluripotency was initially the focus, recent research has demonstrated that partial reprogramming can rejuvenate aged cells without losing their original identity, opening new possibilities for therapeutic applications.[3]

Benefits (evidence-graded)

  • Epigenetic age (cells) — ↓ moderate — partial/chemical reprogramming — C.[3:1][4]
  • Tissue function (mice) — ↑ moderate — muscle, nervous system, vision — C.[5][6][7]
  • Lifespan (progeroid mice) — ↑ moderate — model-specific — C.[5:1]
  • Clinical outcomes (humans) — Insufficient — F.

Grading rubric: A (multiple high-quality meta-analyses of RCTs); B (several RCTs; generally consistent); C (small/heterogeneous RCTs or strong preclinical); D (limited/low-quality or conflicting); E (preclinical/mechanistic only); F (no effect or harm).

Types of Reprogramming

Complete Reprogramming

  • Induced pluripotent stem cells (iPSCs)
  • Full cellular identity reset
  • Potential for complete rejuvenation
  • High technical complexity

Complete reprogramming involves the full conversion of differentiated cells back to a pluripotent state using the Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc).[8] This process completely erases cellular memory and identity, creating cells with embryonic-like properties. While this approach offers the potential for complete rejuvenation, it also carries significant risks including tumor formation and loss of cellular identity.[9]

Partial Reprogramming

  • Limited transcription factor exposure
  • Partial epigenetic reset
  • Maintains cellular identity
  • Lower risk profile

Partial reprogramming represents a breakthrough in the field, allowing for cellular rejuvenation without complete loss of identity. This approach uses transient expression of reprogramming factors to reset epigenetic marks while preserving cellular function.[10] Studies have shown that partial reprogramming can reverse age-related changes in cells while maintaining their specialized functions.[6:1]

Targeted Reprogramming

  • Specific gene or pathway targeting
  • Minimal cellular changes
  • Focused therapeutic approach
  • Enhanced safety

Targeted reprogramming focuses on specific pathways or genes involved in aging, offering a more precise approach to cellular rejuvenation.[7:1] This method aims to address specific age-related changes without affecting the overall cellular identity, potentially reducing side effects while maintaining therapeutic benefits.[4:1]

Chemical Reprogramming

  • Small molecule-based approaches
  • Non-genetic methods
  • Enhanced safety profile
  • Scalable applications

Chemical reprogramming uses small molecules to induce cellular rejuvenation without genetic modification.[11] This approach offers several advantages including enhanced safety, scalability, and the ability to fine-tune the reprogramming process.[12]

Mechanism of Action

Reprogramming works through:

  • Epigenetic mark reset
  • Gene expression restoration
  • Cellular function improvement
  • Tissue regeneration stimulation
  • Age-related damage reversal

Epigenetic Mechanisms

Cellular reprogramming primarily works through the reset of epigenetic marks that accumulate with age.[13] These include DNA methylation patterns, histone modifications, and chromatin remodeling that contribute to cellular aging.[14] The Yamanaka factors can reverse these age-related epigenetic changes, restoring a more youthful cellular state.[15]

Gene Expression Networks

Reprogramming factors activate specific gene expression networks that are associated with pluripotency and cellular rejuvenation.[16] This includes the activation of genes involved in DNA repair, mitochondrial function, and cellular metabolism.[17] The restoration of youthful gene expression patterns contributes to improved cellular function and reduced age-related damage.[18]

Mitochondrial Rejuvenation

One of the key mechanisms of cellular reprogramming involves the rejuvenation of mitochondrial function.[19] Aged cells often exhibit mitochondrial dysfunction, which contributes to cellular aging and death. Reprogramming can restore mitochondrial function and improve cellular energetics.[20]

DNA Repair Enhancement

Cellular reprogramming has been shown to enhance DNA repair mechanisms, which are often compromised in aged cells.[21] This includes the restoration of double-strand break repair and the activation of DNA damage response pathways.[22]

Dosage / protocol (research context)

Approach Factors/agents Exposure pattern Notes
Partial genetic reprogramming OSKM (± c-Myc alternatives) Cyclic, short pulses Balances rejuvenation vs tumor risk[5:2][6:2]
Chemical reprogramming Small-molecule cocktails Transient exposure Non-genetic; scalability potential[11:1][12:1]
Targeted reprogramming Tissue-specific factors Localized delivery Safety and specificity focus[7:2]

Clinical Evidence

Current evidence is limited to:

  • Preclinical animal studies
  • In vitro cell culture experiments
  • Limited human trials
  • Ongoing research

Studies in mice have shown that partial reprogramming can rejuvenate tissues and extend lifespan without inducing tumorigenesis.[5:3] Research has demonstrated that transient expression of reprogramming factors can ameliorate age-associated hallmarks in human cells.[23]

Animal Studies

Landmark studies in mice have demonstrated the potential of cellular reprogramming for longevity. Partial reprogramming has been shown to extend lifespan and improve healthspan in progeroid mice, a model of accelerated aging.[24] These studies have also shown improvements in various age-related phenotypes including muscle function, cardiac function, and cognitive performance.[25]

In Vitro Studies

Extensive in vitro studies have demonstrated that cellular reprogramming can reverse age-related changes in human cells.[26] This includes the restoration of telomere length, improvement in mitochondrial function, and reduction in cellular senescence markers.[27] Studies have also shown that reprogrammed cells exhibit enhanced proliferative capacity and improved stress resistance.[28]

Tissue-Specific Applications

Research has explored the application of cellular reprogramming to specific tissues and organs. Studies have shown that reprogramming can rejuvenate aged muscle stem cells, improving their regenerative capacity.[29] Similar approaches have been applied to cardiac cells, neural cells, and other specialized cell types with promising results.[30]

Clinical Translation

While clinical trials are still limited, several companies and research groups are working to translate cellular reprogramming approaches to human applications.[31] Early-phase clinical trials are being planned to test the safety and efficacy of reprogramming-based therapies for age-related diseases.[32]

Benefits & risks summary (safety)

  • Potential benefits: epigenetic rejuvenation, mitochondrial restoration, improved tissue repair.
  • Key risks: tumorigenesis, loss of cell identity, off-target effects, immune response to vectors.

Precautions (table)

Scenario Precaution What to monitor
In vivo factor delivery Tumor formation, dysplasia Imaging, histopathology, oncogenic markers
c-Myc usage Oncogenic risk Prefer c-Myc-free regimens, surveillance
Viral vectors Insertional mutagenesis, immunity Vector choice, immune monitoring
Ocular/neuronal applications Functional risks Vision/neuro exams, electrophysiology

Startups and industry activity

Billions of dollars have flowed into biotechnology companies aiming to translate cellular reprogramming from the laboratory to the clinic. Major startups are developing partial reprogramming therapies using various delivery modalities—including viral vectors, mRNA-lipid nanoparticles, and small molecules—to treat specific age-related diseases or achieve systemic rejuvenation.

  • Altos Labs (USA/UK): Focused on cellular rejuvenation programming to reverse disease and injury. Supported by significant funding ($3B+), the company is currently in the preclinical stage, establishing institutes to decode cellular health states.[33][34]
  • Retro Biosciences (USA): Utilizing partial reprogramming alongside autophagy and plasma-inspired therapeutics to extend healthy human lifespan. The company is in the preclinical stage, with a focus on T-cell reprogramming and other age-related indications.[35]
  • Turn Biotechnologies (USA): Developing an mRNA-based platform (ERA™) for transient cellular reprogramming. In 2025, Klotho Neurosciences announced an intent to acquire select assets to advance these therapies, following positive feedback from the FDA for dermatological indications.[36][37]
  • Life Biosciences (USA): Pursuing partial epigenetic reprogramming (OSK factors) to treat ocular and liver diseases. The company is in the preclinical stage, demonstrating restoration of visual function in non-human primates and preparing for first-in-human trials.[38][39]
  • NewLimit (USA): Focused on epigenetic reprogramming of immune cells (T cells) and hepatocytes using machine learning to optimize factor combinations. Currently in the preclinical stage, identifying novel transcription factors to restore youthful function.[40]
  • Rejuvenate Bio (USA): Developing gene therapy (AAV) based partial reprogramming. Preclinical studies have shown lifespan extension in wild-type mice and reversal of age-related changes, with a focus on treating specific age-related pathologies.[41][42]
  • Shift Bioscience (UK): Utilizing generative AI to identify safe rejuvenation gene factors that minimize cancer risk. The company raised $16M in seed funding in 2024 to advance its cell simulation platform.[43][44]

Future Directions

In Vivo Reprogramming

The development of in vivo reprogramming approaches represents a major goal for the field.[45] This would allow for direct rejuvenation of aged tissues without the need for cell extraction and transplantation.[46]

Precision Medicine Applications

Cellular reprogramming may enable precision medicine approaches by allowing for personalized rejuvenation strategies based on individual genetic and epigenetic profiles.[47] This could lead to more effective and targeted treatments for age-related diseases.[48]

Combination Therapies

Future research is exploring the combination of cellular reprogramming with other longevity interventions such as senolytics, NAD+ boosters, and lifestyle modifications.[49] These combination approaches may provide synergistic benefits for healthy aging.[50]

See also

References

Evidence Database (core)

Outcome Direction Effect size (units) # Studies Model/participants Evidence grade Notes
Epigenetic age (cells) Small Decrease Moderate (clock units) Several Human cells C Partial/chemical protocols[3:2][4:2][12:2]
Tissue function (muscle/vision) Small Increase Qualitative Multiple Mouse C Muscle regeneration, vision restoration[7:3][29:1]
Lifespan (progeroid mice) Small Increase Model-dependent Few Mouse C Safety window critical[5:4]
Human clinical outcomes — Insufficient 0 — F Early-stage translational field

  1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. https://www.cell.com/cell/fulltext/S0092-8674(06)00976-7 ↩︎

  2. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10(6):678-684. https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(12)00195-7 ↩︎

  3. Olova N, Simpson DJ, Marioni RE, Chandra T. Partial reprogramming induces a steady decline in epigenetic age before loss of somatic identity. Aging Cell. 2019;18(1):e12877. https://onlinelibrary.wiley.com/doi/full/10.1111/acel.12877 ↩︎ ↩︎ ↩︎

  4. Gill D, Parry A, Santos F, et al. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming. Elife. 2022;11:e71624. https://elifesciences.org/articles/71624 ↩︎ ↩︎ ↩︎

  5. Ocampo A, Reddy P, Martinez-Redondo P, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell. 2016;167(7):1719-1733. https://www.cell.com/cell/fulltext/S0092-8674(16)31664-X ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  6. Browder KC, Reddy P, Yamamoto M, et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nat Aging. 2022;2(3):243-253. https://www.nature.com/articles/s43587-022-00183-2 ↩︎ ↩︎ ↩︎

  7. Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-129. https://www.nature.com/articles/s41586-020-2975-4 ↩︎ ↩︎ ↩︎ ↩︎

  8. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872. https://www.cell.com/cell/fulltext/S0092-8674(07)01471-7 ↩︎

  9. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448(7151):313-317. https://www.nature.com/articles/nature05934 ↩︎

  10. Chondronasiou D, Gill D, Mosteiro L, et al. Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming. Aging Cell. 2022;21(3):e13578. https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13578 ↩︎

  11. Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013;341(6146):651-654. https://www.science.org/doi/10.1126/science.1239278 ↩︎ ↩︎

  12. Li X, Zuo X, Jing J, et al. Small-molecule-driven direct reprogramming of mouse fibroblasts into functional neurons. Cell Stem Cell. 2015;17(2):195-203. https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(15)00251-4 ↩︎ ↩︎ ↩︎

  13. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. https://genomebiology.biomedcentral.com/articles/10.1186/gb-2013-14-10-r115 ↩︎

  14. López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153(6):1194-1217. https://www.cell.com/cell/fulltext/S0092-8674(13)00645-4 ↩︎

  15. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371-384. https://www.nature.com/articles/s41576-018-0004-3 ↩︎

  16. Buganim Y, Faddah DA, Cheng AW, et al. Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell. 2012;150(6):1209-1222. https://www.cell.com/cell/fulltext/S0092-8674(12)00895-3 ↩︎

  17. Polo JM, Anderssen E, Walsh RM, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell. 2012;151(7):1617-1632. https://www.cell.com/cell/fulltext/S0092-8674(12)01410-2 ↩︎

  18. Stadtfeld M, Maherali N, Breault DT, Hochedlinger K. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell. 2008;2(3):230-240. https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(08)00062-5 ↩︎

  19. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells. 2010;28(4):721-733. https://onlinelibrary.wiley.com/doi/full/10.1002/stem.404 ↩︎

  20. Suhr ST, Chang EA, Tjong J, et al. Mitochondrial rejuvenation after induced pluripotency. PLoS One. 2010;5(11):e14095. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0014095 ↩︎

  21. Marion RM, Strati K, Li H, et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell. 2009;4(2):141-154. https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(09)00003-2 ↩︎

  22. Suhr ST, Chang EA, Rodriguez RM, et al. Telomere dynamics in human cells reprogrammed to pluripotency. PLoS One. 2009;4(12):e8124. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008124 ↩︎

  23. Sarkar TJ, Quarta M, Mukherjee S, et al. Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells. Nat Commun. 2020;11(1):1545. https://www.nature.com/articles/s41467-020-15174-3 ↩︎

  24. Ocampo A, Reddy P, Martinez-Redondo P, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell. 2016;167(7):1719-1733. https://www.cell.com/cell/fulltext/S0092-8674(16)31664-X ↩︎

  25. Browder KC, Reddy P, Yamamoto M, et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nat Aging. 2022;2(3):243-253. https://www.nature.com/articles/s43587-022-00183-2 ↩︎

  26. Sarkar TJ, Quarta M, Mukherjee S, et al. Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells. Nat Commun. 2020;11(1):1545. https://www.nature.com/articles/s41467-020-15174-3 ↩︎

  27. Chondronasiou D, Gill D, Mosteiro L, et al. Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming. Aging Cell. 2022;21(3):e13578. https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13578 ↩︎

  28. Gill D, Parry A, Santos F, et al. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming. Elife. 2022;11:e71624. https://elifesciences.org/articles/71624 ↩︎

  29. Sinha M, Jang YC, Oh J, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014;344(6184):649-652. https://www.science.org/doi/10.1126/science.1251152 ↩︎ ↩︎

  30. Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-129. https://www.nature.com/articles/s41586-020-2975-4 ↩︎

  31. Chen Y, Lüttmann FF, Schoger E, et al. Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice. Science. 2021;373(6562):1537-1540. https://www.science.org/doi/10.1126/science.abg5159 ↩︎

  32. Abad M, Mosteiro L, Pantoja C, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013;502(7471):340-345. https://www.nature.com/articles/nature12586 ↩︎

  33. Altos Labs. "Altos Labs Launches with $3 Billion to Reverse Cellular Aging." Lifespan.io. 2022. https://www.lifespan.io/news/altos-labs-3-billion-launch-to-reverse-cellular-aging/ ↩︎

  34. The Times. "Inside the $3bn quest to defy ageing that Jeff Bezos is backing." The Times. 2022. https://www.thetimes.com/uk/science/article/jeff-bezos-altos-labs-life-extension-human-ageing-pm5mjl67m ↩︎

  35. Retro Biosciences. "Our Pipeline." Retro Biosciences. 2024. https://www.retro.bio/pipeline ↩︎

  36. Turn Biotechnologies. "FDA Meeting Feedback Puts Turn Biotechnologies on Track." PR Newswire. 2023. https://www.prnewswire.com/apac/news-releases/fda-meeting-feedback-puts-turn-biotechnologies-on-track-to-be-first-longevity-company-taking-cell-rejuvenation-therapy-to-clinic-301965868.html ↩︎

  37. Klotho Neurosciences. "Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies." PR Newswire. 2025. https://www.prnewswire.com/news-releases/klotho-neurosciences-signs-letter-of-intent-to-acquire-select-assets-from-turn-biotechnologies-anchored-by-300-million-global-pharma-partnership-302570344.html ↩︎

  38. Life Biosciences. "Life Bio ready for world’s first partial epigenetic reprogramming trials." Longevity.Technology. 2024. https://longevity.technology/news/life-bio-ready-for-worlds-first-partial-epigenetic-reprogramming-trials/ ↩︎

  39. Life Biosciences. "Life Biosciences Presents New Data at ARDD." Life Biosciences. 2025. https://www.lifebiosciences.com/life-biosciences-presents-new-data-at-ardd-2025-on-the-companys-partial-epigenetic-reprogramming-platform-in-liver-and-ocular-diseases/ ↩︎

  40. NewLimit. "NewLimit raises $130M to push liver mRNA med into clinic." Fierce Biotech. 2023. https://www.fiercebiotech.com/biotech/anti-aging-biotech-newlimit-raises-130m-push-liver-reprogramming-med-clinic ↩︎

  41. Rejuvenate Bio. "Gene Therapy-Mediated Partial Reprogramming Extends Lifespan." Cellular Reprogramming. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10909732/ ↩︎

  42. Rejuvenate Bio. "Rejuvenate Bio shows epigenetic reprogramming extends lifespan." Longevity.Technology. 2023. https://longevity.technology/news/rejuvenate-bio-shows-epigenetic-reprogramming-extends-lifespan-in-normal-mice/ ↩︎

  43. Shift Bioscience. "Shift Bioscience Raises $16M to Advance Cell Simulation AI Platform." Business Wire. 2024. https://www.businesswire.com/news/home/20241015745730/en/Shift-Bioscience-Raises-%2416M-to-Advance-Cell-Simulation-AI-Platform ↩︎

  44. Longevity.Technology. "Shift Bioscience lands $16m to identify safe rejuvenation genes." Longevity.Technology. 2024. https://longevity.technology/news/shift-bioscience-lands-16m-to-identify-safe-rejuvenation-genes/ ↩︎

  45. Chen Y, Lüttmann FF, Schoger E, et al. Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice. Science. 2021;373(6562):1537-1540. https://www.science.org/doi/10.1126/science.abg5159 ↩︎

  46. Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-129. https://www.nature.com/articles/s41586-020-2975-4 ↩︎

  47. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371-384. https://www.nature.com/articles/s41576-018-0004-3 ↩︎

  48. Gill D, Parry A, Santos F, et al. Multi-omic rejuvenation of human cells by maturation phase transient reprogramming. Elife. 2022;11:e71624. https://elifesciences.org/articles/71624 ↩︎

  49. Chondronasiou D, Gill D, Mosteiro L, et al. Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming. Aging Cell. 2022;21(3):e13578. https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13578 ↩︎

  50. Browder KC, Reddy P, Yamamoto M, et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nat Aging. 2022;2(3):243-253. https://www.nature.com/articles/s43587-022-00183-2 ↩︎

Comments

Discussion

Privacy PolicyTerms of UseMedical Disclaimer

The information provided on Longevidence is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new diet, exercise, supplement, or medical protocol.

Longevipedia 2026